European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0","authors":"Antoine Verger, Nelleke Tolboom, Francesco Cicone, Susan M. Chang, Julia Furtner, Norbert Galldiks, Jens Gempt, Eric Guedj, Raymond Y. Huang, Derek R. Johnson, Ian Law, Emilie Le Rhun, Susan C. Short, M. J. Van den Bent, Donatienne Van Weehaeghe, Michael A. Vogelbaum, Patrick Y. Wen, Nathalie L. Albert, Matthias Preusser","doi":"10.1007/s00259-024-07038-5","DOIUrl":"https://doi.org/10.1007/s00259-024-07038-5","url":null,"abstract":"<p>This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neuro-Oncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO). Brain metastases are the most common malignant central nervous system (CNS) tumors. PET imaging with radiolabeled amino acids and to lesser extent [¹⁸F]FDG has gained considerable importance in the assessment of brain metastases, especially for the differential diagnosis between recurrent metastases and treatment-related changes which remains a limitation using conventional MRI. The aim of this guideline is to assist nuclear medicine physicians in recommending, performing, interpreting and reporting the results of brain PET imaging in patients with brain metastases. This practice guideline will define procedure standards for the application of PET imaging in patients with brain metastases in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"98 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142935103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]F-FAPI-42 PET dynamic imaging characteristics and multiparametric quantification of lung cancer: an exploratory study using uEXPLORER PET/CT","authors":"Lijuan Wang, Xingzhu Pan, Shimin Ye, Yanchao Huang, Meng Wang, Li Chen, Kemin Zhou, Yanjiang Han, Hubing Wu","doi":"10.1007/s00259-024-07064-3","DOIUrl":"https://doi.org/10.1007/s00259-024-07064-3","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>To explore the dynamic and parametric characteristics of [¹⁸F]F-FAPI-42 PET/CT in lung cancers.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Nineteen participants with newly diagnosed lung cancer underwent 60-min dynamic [¹⁸F]F-FAPI-42 PET/CT. Time-activity curves (TAC) were generated for tumors and normal organs, with kinetic parameters (<i>K</i>₁, <i>K</i>₂, <i>K</i>₃, <i>K</i>₄, <i>K</i>_i) calculated. A new parameter, the <i>K</i> ratio (<i>K</i>₁ + <i>K</i>₃)/(<i>K</i>₂ + <i>K</i>₄), was introduced to measure net uptake efficiency.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>In primary tumor (PT), [¹⁸F]F-FAPI-42 uptake showed a gradual increase followed by a plateau, contrasting with organs like the thyroid and pancreas, which showed rapid uptake and continuous washout. Compared to non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) lesions reached the plateau earlier (11 min vs. 14 min) but had a lower uptake. During the plateau phase, [¹⁸F]F-FAPI-42 demonstrated slight washout in SCLC, whereas its uptake increased slightly in NSCLC. Lymph node and distant metastases exhibited similar TAC profiles to primary tumors. Kinetic modeling revealed that an irreversible two-compartment model (irre-2TCM) best represented the pharmacokinetics of [¹⁸F]F-FAPI-42 in lung cancer, whereas re-2TCM was better suited for the pancreas and thyroid. Lower <i>K</i>₁, <i>K</i>₂, <i>K</i>₃ and <i>K</i>₄ were observed in PT compared to those in the pancreas and thyroid (<i>P</i> &lt; 0.05), however, the <i>K</i> ratio in PT was found to be 2–3 times higher. SCLC had lower <i>K</i>_<i>i</i> and SUVmean than NSCLC (<i>P</i> &lt; 0.05). Kinetic parameter differences were also observed between PT and metastatic lesions. Larger metastatic lymph nodes exhibited higher <i>K</i>_<i>1</i>, <i>K</i>_<i>i</i>, and <i>K</i> ratio than smaller ones.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Lung cancers exhibit distinct [¹⁸F]F-FAPI-42 dynamic and kinetic characteristics compared to the thyroid gland and pancreas. Differences were also observed between SCLC and NSCLC, primary and metastatic lesions, as well as larger versus smaller lesions. These findings provide valuable insights into the in vivo pharmacokinetics of [¹⁸F]F-FAPI-42, potentially improving the diagnosis of lung cancer.</p><h3 data-test=\"abstract-sub-heading\">Trial registration</h3><p>ChiCTR2100045757. Registered April 24, 2021 retrospectively registered, http//www.chictr.org.cn.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"6 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142929706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nuclear cardiology a solid pillar in the new chronic coronary syndromes ESC guidelines","authors":"Magdalena M. Dobrolinska, Riemer H.J.A. Slart, Marc R. Dweck, Ronny R. Buechel, Paola Anna Erba","doi":"10.1007/s00259-024-07055-4","DOIUrl":"https://doi.org/10.1007/s00259-024-07055-4","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"5 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142929326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FAPI PET for monitoring of rheumatological treatment in multifocal peritoneal nodular fibrosis: a case study","authors":"Lena M. Unterrainer, Stephan T. Ledderose, Sophie C. Kunte, Johannes Toms, Clemens C. Cyran, Adrien Holzgreve, Marcus Unterrainer, Hendrik Schulze-Koops","doi":"10.1007/s00259-024-07052-7","DOIUrl":"https://doi.org/10.1007/s00259-024-07052-7","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"14 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142929327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping the knowledge landscape of the PET/MR domain: a multidimensional bibliometric analysis","authors":"Xiaofei Hu, Jianding Peng, Min Huang, Lin Huang, Qing Wang, Dingde Huang, Mei Tian","doi":"10.1007/s00259-024-07043-8","DOIUrl":"https://doi.org/10.1007/s00259-024-07043-8","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>This study aims to conduct a bibliometric analysis to explore research trends, collaboration patterns, and emerging themes in the PET/MR field based on published literature from 2010 to 2024.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A detailed literature search was performed using the Web of Science Core Collection (WoSCC) database with keywords related to PET/MR. A total of 4,349 publications were retrieved and analyzed using various bibliometric tools, including VOSviewer and CiteSpace.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>The analysis revealed an initial increase in PET/MR publications, peaking at 495 in 2021, followed by a slight decline. The USA, Germany, and China were the most prolific countries, with the USA demonstrating strong collaborative networks. Key institutions included the Stanford University, Technical University of Munich and University of Duisburg-Essen. Prominent authors were primarily from Germany, with significant contributions from University Hospital Essen. Major journals in the field included the European Journal of Nuclear Medicine, Journal of Nuclear Medicine, and Physics in Medicine and Biology. Emerging research areas focused on oncology, neurological disorders, and cardiovascular diseases, with keywords such as “prostate cancer,” “Alzheimer’s disease,” and “breast cancer” showing high research activity. Recent trends also highlight the growing integration of AI, particularly deep learning, to improve imaging reconstruction and diagnostic accuracy.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>The findings emphasize the need for continuous investment, strategic planning, and technological innovations to expand PET/MR’s clinical applications. Future research should focus on optimizing imaging techniques, fostering international collaborations, and integrating emerging technologies like artificial intelligence to enhance PET/MR’s diagnostic and therapeutic potential in precision medicine.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"34 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142924967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular disease and radiopharmaceutical therapies- an underestimated risk?","authors":"Michael Lassmann, Uta Eberlein, Frederik A Verburg","doi":"10.1007/s00259-024-07039-4","DOIUrl":"https://doi.org/10.1007/s00259-024-07039-4","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142913987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preliminary evaluation of a novel PSMA-targeting radiopharmaceutical [68Ga]Ga/[177Lu]Lu–NYM032 for theranostic use in prostate cancer","authors":"Haitian Fu, Huihui He, Yanjuan Wang, Wenjin Li, Yihui Luo, Liping Chen, Yuanyuan Mi, Chengwen Sun, Yong Mao, Chunjing Yu","doi":"10.1007/s00259-024-07046-5","DOIUrl":"https://doi.org/10.1007/s00259-024-07046-5","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>A novel theranostic radiopharmaceutical targeting prostate-specific membrane antigen (PSMA), [⁶⁸Ga]Ga/[¹⁷⁷Lu]Lu–NYM032, was developed and its diagnostic and therapeutic potential in the treatment of prostate cancer (PCa) was preliminarily evaluated.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>The diagnostic efficacy of the PET tracer [⁶⁸Ga]Ga–NYM032 was first evaluated in PSMA-positive xenograft-bearing models (LNCaP models), followed by evaluation in 10 PCa patients using [⁶⁸Ga]Ga–PSMA617 a comparator. Finally, the therapeutic potential of [¹⁷⁷Lu]Lu–NYM032 was evaluated in LNCaP models.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>[⁶⁸Ga]Ga/[¹⁷⁷Lu]Lu–NYM032 was well-tolerated, and no adverse events were observed in the preclinical and clinical studies. [⁶⁸Ga]Ga–NYM032 demonstrated PSMA specificity and high radioactive uptake in LNCaP tumors. [⁶⁸Ga]Ga–NYM032 uptake (SUV_max) did not differ from [⁶⁸Ga]Ga–PSMA617 uptake in the same in situ lesions at the same p.i. time point (median 9.40 vs. 6.85, <i>P</i> = 0.123, <i>n</i> = 8). Compared with [⁶⁸Ga]Ga–PSMA617 uptake, [⁶⁸Ga]Ga–NYM032 uptake was significantly higher in osseous metastases (median 5.10 vs. 3.88, <i>P</i> &lt; 0.001, <i>n</i> = 48), and higher in lymph node metastases (median 7.81 vs. 5.46, <i>n</i> = 2). [¹⁷⁷Lu]Lu–NYM032 showed high aggregation in the lesions of LNCaP models and long retention times. [¹⁷⁷Lu]Lu–NYM032 could inhibit tumor progression in LNCaP models, and its therapeutic efficiency strengthened with increasing radio-dosage (18.5–74 MBq/mouse). The tumor volume in the high radio-dosage treatment group (74 MBq/mouse) was significantly smaller than that in the blank control group at 21 days p.i. (107.14 ± 13.68 mm³ vs. 1351.86 ± 249.98 mm³, <i>P</i> &lt; 0.001, <i>n</i> = 7).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>[⁶⁸Ga]Ga/[¹⁷⁷Lu]Lu-NYM032 has considerable potential as a novel and powerful theranostic radiopharmaceutical for PCa.</p><h3 data-test=\"abstract-sub-heading\">Trial registration</h3><p>The clinical evaluation of this study was registered at <i>Clinicaltrial.gov</i> (NCT06389695) on 29 Apr, 2024.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"160 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical investigation of [149Tb]Tb-DOTATATE and [149Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy","authors":"Ana Katrina Mapanao, Sarah D. Busslinger, Avni Mehta, Kristel Kegler, Chiara Favaretto, Pascal V. Grundler, Zeynep Talip, Ulli Köster, Karl Johnston, Roger Schibli, Nicholas P. van der Meulen, Cristina Müller","doi":"10.1007/s00259-024-07035-8","DOIUrl":"https://doi.org/10.1007/s00259-024-07035-8","url":null,"abstract":"&lt;h3 data-test=\"abstract-sub-heading\"&gt;Purpose&lt;/h3&gt;&lt;p&gt;Terbium-149 is a short-lived α-particle emitter, potentially useful for tumor-targeted therapy. The aim of this study was to investigate terbium-149 in combination with the somatostatin receptor (SSTR) agonist DOTATATE and the SSTR antagonist DOTA-LM3. The radiopeptides were evaluated to compare their therapeutic efficacy in vitro and in vivo.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Methods&lt;/h3&gt;&lt;p&gt;Terbium-149 was produced at ISOLDE/CERN and chemically purified at the Paul Scherrer Institute. Radiolabeling of somatostatin analogues with [&lt;sup&gt;149&lt;/sup&gt;Tb]TbCl&lt;sub&gt;3&lt;/sub&gt; was performed under standard labeling conditions at pH 4.5. Cell viability (MTT) and survival assays (colony forming) assays were performed after 16–18 h exposure of SSTR-positive AR42J rat pancreatic tumor cells to various activity concentrations of [&lt;sup&gt;149&lt;/sup&gt;Tb]Tb-DOTATATE and [&lt;sup&gt;149&lt;/sup&gt;Tb]Tb-DOTA-LM3. DNA double-strand breaks were determined using immunofluorescence imaging of γ-H2A.X and 53BP1. Therapy studies were performed with AR42J tumor-bearing mice injected with 1 × 5 MBq or 2 × 5 MBq of the respective radiopeptide. The tolerability of up to 40 MBq [&lt;sup&gt;149&lt;/sup&gt;Tb]Tb-DOTATATE or 40 MBq [&lt;sup&gt;149&lt;/sup&gt;Tb]Tb-DOTA-LM3 was assessed with regard to undesired effects to the bone marrow and kidneys in immunocompetent mice without tumors.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Results&lt;/h3&gt;&lt;p&gt;The radiolabeling of peptides was achieved at molar activities of up to 20 MBq/nmol at ≥ 98% radiochemical purity. AR42J cell viability was reduced in an activity-dependent manner, with [&lt;sup&gt;149&lt;/sup&gt;Tb]Tb-DOTA-LM3 being slightly more potent than [&lt;sup&gt;149&lt;/sup&gt;Tb]Tb-DOTATATE (EC&lt;sub&gt;50&lt;/sub&gt;: 0.5 vs. 1.2 kBq/mL). Both radiopeptides induced a similar number of γ-H2A.X and 53BP1 foci per nuclei, which indicated DNA damage in AR42J tumor cells. Injection of tumor-bearing mice with 1 × 5 MBq radiopeptide resulted in median survival times of 16.5 days and 19 days for [&lt;sup&gt;149&lt;/sup&gt;Tb]Tb-DOTATATE and [&lt;sup&gt;149&lt;/sup&gt;Tb]Tb-DOTA-LM3, respectively, as compared to only 8 days for untreated control mice. Application of 2 × 5 MBq of the radiopeptides further extended the median survival times to 30 days and 29 days, respectively. The blood cell counts and values for blood plasma biomarkers of treated mice without tumors were similar to those of untreated controls. Renal accumulation of [&lt;sup&gt;99m&lt;/sup&gt;Tc]Tc-DMSA was similar in all mice, indicating normal kidney function.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Conclusion&lt;/h3&gt;&lt;p&gt;&lt;sup&gt;149&lt;/sup&gt;Tb-based radiopeptides effectively reduced the viability of tumor cells in vitro as well as the tumor growth in mice without causing relevant adverse events, irrespective of whether the SSTR agonist or antagonist was employed. These data encourage further preclinical application of terbium-149 to evaluate its potential in combination with other tumor-targeting agents.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-hea","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"16 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]FDG PET/CT for predicting neoadjuvant PD-L1 blockade monotherapy treatment response in patients with locally advanced esophageal squamous cell carcinoma: a preliminary study","authors":"Runjun Yang, Han Tang, Yunze Xie, Danjie Cai, Yibo He, Zhe Zheng, Yu Lin, Huaping Gao, Wenxin Tang, Yihan Yan, Lijie Tan, Hongcheng Shi","doi":"10.1007/s00259-024-07051-8","DOIUrl":"https://doi.org/10.1007/s00259-024-07051-8","url":null,"abstract":"&lt;h3 data-test=\"abstract-sub-heading\"&gt;Purpose&lt;/h3&gt;&lt;p&gt;To investigate the predictive value of 2-[18F]-fluoro-2-deoxy-D-glucose ([&lt;sup&gt;18&lt;/sup&gt;F]FDG) PET/CT for evaluating primary tumor (PT) and lymph node (LN) responses after neoadjuvant programmed death-ligand 1 (PD-L1) blockade monotherapy in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC).&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Methods&lt;/h3&gt;&lt;p&gt;In the single-arm phase 1b NATION-1907 trial (NCT04215471), 23 patients with LA-ESCC received two cycles of neoadjuvant PD-L1 blockade Adebrelimab followed by surgery. Among these, 18 patients underwent [&lt;sup&gt;18&lt;/sup&gt;F]FDG PET/CT scans both before immunotherapy and prior to surgery. Standardized uptake value corrected for lean body mass (SUL)-derived parameters, including SUL&lt;sub&gt;max&lt;/sub&gt; and SUL&lt;sub&gt;peak&lt;/sub&gt;, were documented for PTs and LNs. Lesions &gt; 1cm&lt;sup&gt;3&lt;/sup&gt; were segmented using thresholds of 41% and 50% of SUL&lt;sub&gt;max&lt;/sub&gt;, respectively, following European Association of Nuclear Medicine (EANM) guidelines, with metabolic tumor volume (MTV) and total lesion glycolysis (TLG) calculated. Percentage changes of all metabolic parameters were also recorded. Residual viable tumor ≤ 33% were classified as well-responders, whereas residual viable tumor &gt; 33% were classified as poor-responders based on histological evaluation.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Results&lt;/h3&gt;&lt;p&gt;In the PT analysis, 10 patients were classified as PT well-responders and 8 as PT poor-responders. All post-treatment metabolic parameters, except MTV, were significantly lower in well-responders compared to poor-responders. The %ΔMTV, %ΔTLG were significantly higher in the poor-responder group (all &lt;i&gt;P&lt;/i&gt; &lt; 0.05). ROC curves indicated %ΔMTV&lt;sub&gt;41&lt;/sub&gt; exhibited optimum performance in predicting well-responders, with an AUC of 0.875 (cut-off: -31.01). Furthermore, %ΔMTV&lt;sub&gt;41&lt;/sub&gt; significantly predicted patients' recurrence-free survival (RFS) (&lt;i&gt;P&lt;/i&gt; &lt; 0.1). In the LN analysis, 7 LNs were classified as well-responders and 10 as poor-responders. Pre-treatment SUL&lt;sub&gt;max&lt;/sub&gt;, SUL&lt;sub&gt;peak&lt;/sub&gt; were significantly lower in poor-responders compared to well-responders. Post-treatment MTV&lt;sub&gt;50&lt;/sub&gt; and all percentage changes in parameters were significantly higher in the poor-responder group (all &lt;i&gt;P&lt;/i&gt; &lt; 0.05). Receiver operating characteristic curve (ROC) analysis indicated %ΔTLG&lt;sub&gt;50&lt;/sub&gt; had excellent predictive performance for well-responders, with an AUC of 1.000 (cut-off: -7.5). However, there was no significant correlation between the metabolic response evaluations for PTs and LNs.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Conclusion&lt;/h3&gt;&lt;p&gt;The metabolic parameters of [&lt;sup&gt;18&lt;/sup&gt;F]FDG PET/CT, particularly %ΔMTV and %ΔTLG, could effectively predict well-responders among both PTs and LNs to neoadjuvant PD-L1 blockade monotherapy in LA-ESCC, which may facilitate personalized immunotherapy and serve as a stratifica","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"25 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging","authors":"Michael T. Nedelcovych, Ranjeet P. Dash, Ying Wu, Eun Yong Choi, Rena S. Lapidus, Pavel Majer, Andrej Jančařík, Diane Abou, Marie-France Penet, Anastasia Nikolopoulou, Alex Amor-Coarasa, John Babich, Daniel L. Thorek, Rana Rais, Clemens Kratochwil, Barbara S. Slusher","doi":"10.1007/s00259-024-07044-7","DOIUrl":"https://doi.org/10.1007/s00259-024-07044-7","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Prostate-specific membrane antigen (PSMA) radioligand therapy is a promising treatment for metastatic castration-resistant prostate cancer (mCRPC). Several beta or alpha particle-emitting radionuclide-conjugated small molecules have shown efficacy in late-stage mCRPC and one, [[177Lu]Lu]Lu-PSMA-617, is FDA approved. In addition to tumor upregulation, PSMA is also expressed in kidneys and salivary glands where specific uptake can cause dose-limiting xerostomia and potential for nephrotoxicity. The PSMA inhibitor 2-(phosphonomethyl)pentanedioic acid (2-PMPA) can prevent kidney uptake in mice, but also blocks tumor uptake, precluding its clinical utility. Preferential delivery of 2-PMPA to non-malignant tissues could improve the therapeutic window of PSMA radioligand therapy.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A tris(isopropoxycarbonyloxymethyl) (TrisPOC) prodrug of 2-PMPA, JHU-2545, was synthesized to enhance 2-PMPA delivery to non-malignant tissues. Mouse pharmacokinetic experiments were conducted to compare JHU-2545-mediated delivery of 2-PMPA to plasma, kidney, salivary glands, and C4-2 prostate tumor xenograft. Imaging studies were conducted in rats and mice to measure uptake of PSMA PET tracers in kidney, salivary glands, and prostate tumor xenografts with and without JHU-2545 pre-treatment.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>JHU-2545 resulted in approximately 3- and 53-fold greater exposure of 2-PMPA in rodent salivary glands (18.0 ± 0.97 h*nmol/g) and kidneys (359 ± 4.16 h*nmol/g) versus prostate tumor xenograft (6.79 ± 0.19 h*nmol/g). JHU-2545 also blocked rodent kidneys and salivary glands uptake of the PSMA PET tracers [68Ga]Ga-PSMA-11 and [18 F]F-DCFPyL by up to 85% with little effect on tumor.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>JHU-2545 pre-treatment may enable greater cumulative administered doses of PSMA radioligand therapy, possibly improving safety and efficacy.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"33 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142911712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}